MoreLatest news
January 2010 7:00:00 AM
EMA starts formal review of Glybera® dossier
read more
read more
January 2010 7:00:00 AM
AMT submits its lead product Glybera® Application for Marketing Authorisation Application to EMA
read more
read more
January 2010 2:08:00 AM
AMT Receives Innovation Credit from Dutch Government for Duchenne Muscular Dystrophy
read more
read more
December 2009 1:24:00 AM
Amsterdam Molecular Therapeutics (AMT) successfully raises EUR 5 million via a Convertible Bond issue with shareholder Forbion
read more
read more
December 2009
AMT Announces Management Changes in light of refocused strategy
read more
read more
November 2009
AMT Provides Business Update for the Third Quarter 2009
read more
read more
November 2009
AMT Successful in Preclinical Treatment of DMD
read more
read more
October 2009
AMT Uses PimTim to Design Packaging for Gene Therapy
read more
read more
October 2009
AMT Starts Development LPLChip(TM) with Progenika
read more
read more
October 2009 1:01:00 AM
AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
read more
read more
